<DOC>
	<DOCNO>NCT00879333</DOCNO>
	<brief_summary>This study design assess safety efficacy RAD001 monotherapy patient advance gastric cancer progress one two line prior chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy RAD001 ( Everolimus ) Monotherapy Plus Best Supportive Care Patients With Advanced Gastric Cancer ( AGC )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female patient &gt; 18 year old Histologically cytologically confirm documented gastric adenocarcinoma Documented progression 1 2 prior chemotherapy treatment advance disease ECOG Performance Status &lt; 2 Lab parameter within specifically define interval Able provide write informed consent Patients receive &gt; 2 prior systemic therapy advance disease Administration another anticancer therapy within 3 week prior randomization Chronic treatment steroid another immunosuppressive agent Major surgery within 2 week prior randomization Patients CNS metastases Any severe and/or uncontrolled medical condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gastric cancer ,</keyword>
	<keyword>advanced gastric cancer ,</keyword>
	<keyword>stomach neoplasm ,</keyword>
	<keyword>stomach disease ,</keyword>
	<keyword>adenocarcinoma stomach ,</keyword>
	<keyword>GI neoplasm</keyword>
</DOC>